SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eli Lilly Reports Improved One-Year Phase 3b Efficacy Data

Phase 3b data show improved one-year efficacy for Taltz and Zepbound in psoriatic arthritis and obesity.

LLY

Related stories